CD164 and infection: The anti-CD164 MAb N6B6, which was demonstrated to bind a conformationally dependent backbone epitope encompassing the cysteine-rich domain between the two mucin domains (42, 49), blocked infection by rLCMV-mCherry in a dose-dependent manner (Fig. 3D).